Group 1 - The core point of the article is that Suzhou Kaituo Pharmaceutical Co., Ltd. has obtained a patent for a compound related to thioethylurea, indicating its ongoing innovation in the pharmaceutical sector [1] - The patent, titled "An Intermediate for Thioethylurea Drugs and Its Preparation Method and Use," was granted with the announcement number CN116829554B, and the application date was January 2022 [1] - Suzhou Kaituo Pharmaceutical was established in 2009 and is primarily engaged in research and experimental development, with a registered capital of 87.057437 million RMB [1] Group 2 - The company has made investments in four enterprises and has participated in 11 bidding projects [1] - Suzhou Kaituo Pharmaceutical holds 42 trademark registrations and 44 patent registrations, along with 31 administrative licenses [1]